Yes it can be approved in Europe based on PFS alone (provided OS is not negative at least)
A Conditional Approval is the fastest route for an onco drug to be approved in Europe, I think Aldo is a very good fit for that.
Management should be seeking such in Europe. given that aldox is the same compound as doxo the chance of a worse OS is very low. Could they seek the European conditional approval based on the STS PII trial?
That is a very good question and I would like to hear some discussion on that. But add to that, there is a profound decrease or perhaps elimination of the risk of cardiotoxicity with Aldo versus Doxorubicin. That fact in combination with the PFS advantage of Aldo, I would think would be enough for approval. IMO